Mallinckrodt Plc MNK:NYSE (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
92.51 1.19   1.30% 1,614,8662.1M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/8/2014

Latest News Headlines for Mallinckrodt Plc

Project Update, Awards, Appointment, Product Launch, and Sponsorship - Research Reports on D.R. Horton, Mallinckrodt, Illumina, Ventas and Capital One Financial

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, September 29, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding D.R. Horton Inc. (NYSE: DHI), Mallinckrodt PLC (NYSE: MNK), Illumina Inc. (NASDAQ: ILMN), Ventas, Inc. (NYSE: VTR) and Capital One Financial Corporation (NYSE: COF). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6815-100free.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. On June 28, 2013, Covidien plc completed the separation of its Pharmaceuticals business and transferred the Pharmaceuticals business to Mallinckrodt. In March 2014, the Company acquired Cadence Pharmaceuticals, Inc. In August 2014, Mallinckrodt Plc acquired Questcor Pharmaceuticals, Inc. On August 15, 2014, Lucio Co, through VFC Land Resources Inc, acquired 3.092% interest in Makati-based Philippine Bank of Communications.

http://mallinckrodt.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open91.18
Previous Close92.51
Day High--
Day Low--
52 Week High10/6/2014 | 94.01
52 Week Low10/30/2013 | 41.67
% Off 52 Week High-1.60%
% Off 52 Week Low122.01%
Beta (5 Yr)--
Volatility Avg10/8/2014 | 32.74
10-Day Avg. Volume2,140,824
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/27/2014 | 1.11
P/E Ratio6/27/2014 | 83.0
Market CapLarge Cap | 10.5B
Shares Outstanding113.69M
Float113.0M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short14.29M
Short Ratio5.9
Short % of Float12.65%
As of 9/15/2014

Peers Information HelpMNK Mallinckrodt Plc vs. Peers